Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01951339 · ClinicalTrials.gov registry record · NA
Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes
A NA study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- NA
- Development phase
- 36
- Enrollment target
NCT01951339 is a NA study that has completed, run by University of Colorado, Denver. The registered enrollment target is 36 participants.
The verdict
NCT01951339, a NA study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
Study Summary
The goal of this study is to examine whether sitagliptin, an agent which enhances the action of hormones that control the release of insulin and is already in clinical use for type 2 diabetes, might also improve functional exercise capacity. Specific aims: 1\. To test whether sitagliptin will improve functional exercise capacity in persons with type 2 diabetes compared to glimepiride. 1a. The primary outcome will be peak oxygen consumption (VO2peak) and oxygen uptake kinetics (VO2 kinetics). 1b. Secondary outcomes include cardiac function, endothelial function and tissue oxygen saturation (STO2) as well as health-related quality of life. 2\. To evaluate the impact of sitagliptin on muscle mitochondrial function 2a. The primary outcome to address this aim will be 31P measurements (phosphocreatine, free inorganic phosphate, adenosine triphosphate peaks, adenosine diphosphate and pH) Impact: Novel approaches are needed to decrease excess cardiovascular morbidity and mortality in diabetes. Diabetes impairs cardiovascular fitness and thereby mortality. A demonstration that sitagliptin improves cardiovascular fitness, (and possibly mitochondrial function) will provide important new data pertinent to the management of diabetes and pre-diabetes.
Interventions
- DRUG Placebo
- DRUG Sitagliptin
- DRUG Glimepiride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2013-10 |
| Est. Completion | 2018-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01951339
The ClinicalTrials.gov registry entry for NCT01951339 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01951339 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01951339 about?
NCT01951339 is a clinical study titled "Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes". The goal of this study is to examine whether sitagliptin, an agent which enhances the action of hormones that control the release of insulin and is already in clinical use for type 2 diabetes, might also improve functional exercise capacity. Specific aims: 1\. To test whether sitagliptin will impr...
What is the current status of trial NCT01951339?
This trial is currently completed. It is a NA study. The enrollment target is 36 participants. The study started on 2013-10. Estimated completion is 2018-06.
What interventions are being tested in trial NCT01951339?
The interventions under investigation include: Placebo (DRUG), Sitagliptin (DRUG), Glimepiride (DRUG).
Who is sponsoring clinical trial NCT01951339?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.